Predictive Oncology, Inc.
(NASDAQ : POAI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 0.29%495.431.0%$1075.59m
ABTAbbott Laboratories 2.21%113.290.8%$980.43m
DHRDanaher Corp. -0.54%266.990.7%$824.09m
MDTMedtronic Plc 0.46%125.440.6%$625.70m
ISRGIntuitive Surgical, Inc. 0.09%906.232.3%$456.46m
BDXBecton, Dickinson & Co. 0.20%240.701.0%$384.58m
ALGNAlign Technology, Inc. 3.10%624.596.3%$313.62m
DXCMDexCom, Inc. -0.67%428.857.8%$304.86m
SYKStryker Corp. -0.37%261.671.3%$292.07m
BSXBoston Scientific Corp. 0.22%43.891.0%$277.94m
BAXBaxter International, Inc. 0.58%81.401.8%$239.12m
EWEdwards Lifesciences Corp. -0.64%104.090.4%$239.10m
ZBHZimmer Biomet Holdings, Inc. -0.35%163.891.7%$235.51m
AAgilent Technologies, Inc. -0.18%146.971.6%$235.19m
IDXXIDEXX Laboratories, Inc. -1.32%607.733.8%$213.16m

Company Profile

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.